Seniprutug, also known as BCD-180 and marketed in Russia as Tribuvia, is a recombinant humanized monoclonal antibody designed to selectively target T-cell receptor beta variable 9 (TRBV9). It is an IgG1-kappa antibody developed for targeted depletion of pathogenic TRBV9-positive T-cell populations associated with axial spondyloarthritis.
Seniprutug received approval in Russia in 2024 for the treatment of radiographic axial spondyloarthritis in the appropriate patient population. It represents a distinct biological approach aimed at selectively addressing disease-associated T-cell clones rather than producing broad systemic immunosuppression.
Seniprutug is a full-length, naked, monospecific IgG1-kappa monoclonal antibody. FDA's Global Substance Registration System describes the antibody as a humanized anti-TRBV9 monoclonal antibody with human IgG1 constant regions and a kappa light chain, produced using Chinese hamster ovary (CHO) cells.
Key identity information:
Unlike conventional chemical APIs, Seniprutug is a complex biological macromolecule whose quality is characterized through a combination of identity, protein concentration, purity, aggregation, charge variants, structural integrity, potency, glycosylation and microbiological/viral safety controls.
It should therefore not be assigned conventional small-molecule specifications such as melting point, residue on ignition or specific rotation unless these are specifically established in an approved drug-substance specification.
Seniprutug binds to TRBV9, a variable region of the T-cell receptor beta chain. The therapeutic concept is to selectively eliminate TRBV9-positive pathogenic T-cell populations through antibody-dependent cellular cytotoxicity (ADCC). This targeted mechanism is intended to reduce disease-associated immune activity while avoiding indiscriminate depletion of the broader immune system.
Seniprutug is associated primarily with radiographic axial spondyloarthritis (r-axSpA), including ankylosing spondylitis. Clinical studies have evaluated BCD-180 in patients with active radiographic axial spondyloarthritis. In the Phase 2 ELEFTA study, 5 mg/kg and 7 mg/kg dosing produced ASAS40 responses of 40.8% and 51.4%, respectively, at Week 24 versus 24% with placebo.
The molecule is also being evaluated in broader axial spondyloarthritis development programs.
Seniprutug API requires a biologics-oriented analytical control strategy. Appropriate quality testing may include:
Numerical acceptance criteria should be taken from the manufacturer's approved drug-substance specification or applicable regulatory dossier rather than invented as universal values.
Seniprutug is produced as a recombinant monoclonal antibody using CHO cells. FDA GSRS specifically identifies the molecule as being produced in Chinese hamster ovary cells.
Biological manufacturing requires controlled upstream cell culture, downstream purification, viral clearance, formulation, sterile processing and extensive analytical characterization.
Seniprutug is a protein therapeutic and does not behave like a conventional crystalline small molecule. Therefore, conventional API parameters such as melting point, optical rotation and residue on ignition are generally not suitable universal release descriptors.
The marketed Russian formulation is a 25 mg/mL concentrate for solution for infusion and is described as a clear or slightly opalescent liquid ranging from colorless to light brown/light yellow.
The approved Russian product is supplied as a sterile concentrate for intravenous infusion in glass vials at 25 mg/mL, with presentations including 1 mL, 1.6 mL and 5 mL formats.
For API manufacturing and commercial handling, storage conditions should follow the validated drug-substance stability protocol and approved specification. Do not assign an API storage temperature from the finished-product label unless it applies specifically to the API.
A commercial Seniprutug API package may include, as applicable:
Seniprutug requires specialized biologics manufacturing and analytical capabilities because it is a recombinant monoclonal antibody rather than a conventional synthetic pharmaceutical ingredient. A suitable manufacturing program should therefore emphasize controlled CHO-cell production, purification, characterization, potency testing, impurity control and batch-to-batch consistency.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |